Search

Displaying results 4061 - 4070 of 10000 in total
  1. Drug

    Cannabidivarin

    go.drugbank.com/drugs/DB14050
    Investigational

    In October 2017 CBDV was given orphan designation by the European Medicines Agency for use in Rett Syndrome [L2952] and again in February 2018 for treatment of Fragile X Syndrome [L2951]. … , which is a member of a large family of ion channels that are involved in the onset and progression of several types of epilepsy.

    Synonyms: 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-propylbenzene-1,3-diol
  2. Drug

    Zosuquidar

    go.drugbank.com/drugs/DB06191
    Investigational

    Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States.

  3. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. … DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.

  4. Drug

    UC-781

    go.drugbank.com/drugs/DB05871
    Investigational

    UC-781 is a thiocarboxanilide non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a topical microbicide targeted against the AIDS virus.

  5. Drug

    Roxatidine acetate

    go.drugbank.com/drugs/DB08806
    Investigational

    Roxatidine acetate is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.

  6. Drug

    Certoparin

    go.drugbank.com/drugs/DB09261
    Approved

    Certoparin is part of the heparins of low molecular weight that presents high activity against the coagulation factor Xa. It is normally used to prevent deep venous thrombosis.

  7. Drug

    Darifenacin

    go.drugbank.com/drugs/DB00496
    ApprovedInvestigational

    It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments. … This block reduces the urgency to urinate and so it should not be used in people with urinary retention.

  8. Drug

    Rapacuronium

    go.drugbank.com/drugs/DB04834
    ApprovedWithdrawn

    Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.

  9. Drug

    Ethotoin

    go.drugbank.com/drugs/DB00754
    Approved

    Ethotoin is no longer commonly used. … Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression.

  10. Drug

    ZEN-012

    go.drugbank.com/drugs/DB06042
    Experimental

    ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition. … It is developed for the treatment of solid tumors.